FiercePharma4d
Amylyx names chief commercial officer as GLP-1 receptor antagonist launch plans start ramping up
Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.
BioSpace13h
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
FierceBiotech6h
Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO
Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...
STAT2h
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?
We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a ...
BioSpace3d
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Joplin Globe4d
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership ...
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...